Trials / Completed
CompletedNCT03136822
DERMALIX Efficacy on Diabetic Foot Ulcers
Clinical Evaluation of the Wound Dressing Impregnated With Microparticules (DERMALIX) on Diabetic Foot Ulcers
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Dermis Pharma · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
(DERMALIX) (Patent number: PCT/TR2014/000251) is a bioactive wound dressing that was developed by Ege University School of Pharmacy Department of Pharmaceutical Technology. This dressing has been categorised as Class III medical device. This clinical study will be conducted in patients with diabetic foot ulcers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Standard Dressing | Standard dressing is applied for treatment of diabetic foot ulcers |
| DEVICE | DERMALIX | DERMALIX, a class III Medical Device will be applied in addition to standard dressing |
Timeline
- Start date
- 2017-04-26
- Primary completion
- 2018-05-02
- Completion
- 2018-08-01
- First posted
- 2017-05-02
- Last updated
- 2018-08-03
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT03136822. Inclusion in this directory is not an endorsement.